Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Tipo del documento
Intervalo de año de publicación
1.
Rev Argent Microbiol ; 53(4): 309-313, 2021.
Artículo en Español | MEDLINE | ID: mdl-33618899

RESUMEN

A descriptive observational and cross-sectional study was carried out. The clinical characteristics, etiologic agents, treatments and outcome of 33 cases of tinea capitis in the Mycology Unit at Francisco J. Muñiz Hospital of Buenos Aires City between January 2015 and December 2019 were analyzed. The median age of the patients was 7 years, 21 of whom were male, 3 were HIV-positive and 22 had pets. The isolated etiologic agents were the following: Microsporum canis in 22 cases, Trichophyton tonsurans in 8, Nannizzia gypsea in 2 and Trichophyton mentagrophytes in one patient. Suppurative tinea capitis (krion Celsi) was detected in 10 cases and the same number of patients presented other skin locations of their dermatophytosis in addition to those in the scalp. Twenty-one cases were orally treated with griseofulvin and 12 with terbinafine. Those patients with suppurative tinea capitis received drops of betamethasone by mouth besides the antifungal drugs. All patients had good clinical and mycological response to the treatments, all lesions disappeared, and mycological studies turned negative by the end of the treatments. We conclude that both drugs were effective for the treatment of tinea capitis; however, lesions in those cases receiving terbinafine involuted more slowly.


Asunto(s)
Naftalenos , Tiña del Cuero Cabelludo , Antifúngicos/uso terapéutico , Niño , Estudios Transversales , Griseofulvina/uso terapéutico , Humanos , Masculino , Terbinafina/uso terapéutico , Tiña del Cuero Cabelludo/diagnóstico , Tiña del Cuero Cabelludo/tratamiento farmacológico , Tiña del Cuero Cabelludo/epidemiología , Trichophyton
2.
Rev. iberoam. micol ; 33(1): 55-57, ene.-mar. 2016. ilus
Artículo en Inglés | IBECS | ID: ibc-149377

RESUMEN

The case of a 59-year-old female born in Buenos Aires (Argentina) is presented. She had been diagnosed with HIV in 2007 and received highly active antiretroviral therapy until 2011; she also suffered from diabetes type 2. She had received empirical treatment (pyrimethamine-clindamycin) for cerebral toxoplasmosis. Fifteen days later she suffered a drug-induced skin disorder and was treated in the Dermatology Service of the Hospital Muñiz with corticosteroids. After five weeks she was readmitted to the Infectious Disease Unit due to asthenia, weight loss, left hip pain and weakness in all four limbs. Septic arthritis and aseptic hip necrosis were ruled out. Blood cultures were positive for Staphylococcus aureus and Escherichia coli. The patient received intravenous antibiotics, but before being discharged Acinetobacter baumannii was isolated from blood, catheter and urine cultures, and a new series of antibiotics were prescribed. On the 3rd day she presented encephalic facies, changes of behaviour and disorientation, without nuchal rigidity, Kernig and Brudzinski signs or focal signs. An X-ray computed tomography did not show parenchymal lesions. A yeast identified as Candida albicans was isolated in a cerebrospinal fluid culture. The same yeast was recovered in a new cerebrospinal fluid sample. The isolate was susceptible to amphotericin B and susceptible dose dependent to fluconazole. The patient was treated with amphotericin B (0.7 mg/kg plus 800 mg fluconazole daily). Three weeks later, new cerebrospinal fluid cultures were negative. Unfortunately, the patient died soon afterwards (AU)


No disponible


Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Micología/métodos , Micología/tendencias , Staphylococcus aureus , Staphylococcus aureus/aislamiento & purificación , Escherichia coli , Escherichia coli/aislamiento & purificación , Vancomicina/uso terapéutico , Piperacilina/uso terapéutico , Diabetes Mellitus Tipo 2/complicaciones , Toxoplasmosis/complicaciones , Toxoplasmosis/tratamiento farmacológico , Astenia/complicaciones , Cefalotina/uso terapéutico , Ciprofloxacina/uso terapéutico , Inmunodifusión/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA